Instrument Inactif

Communiqués Dimension Therapeutics Inc

Actions

US25433V1052

Recherche biotechnologique et médicale

Communiqués

03/10/17	Dimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a Fair Price?	PR
02/10/17	Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”	GL
19/09/17	Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”	GL
18/09/17	Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx	GL
05/09/17	Dimension Therapeutics : OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors	PR
31/08/17	Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information	BU
31/08/17	Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency	GL
30/08/17	Dimension Therapeutics : REGENXBIO to Acquire Dimension Therapeutics	PU
25/08/17	Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional Information	BU
25/08/17	DIMENSION THERAPEUTICS, INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout	BU
25/08/17	Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Dimension Therapeutics, Inc. to REGENXBIO Inc. is Fair to Shareholders	BU
08/08/17	Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update	GL
24/07/17	Dimension Therapeutics Announces Management Change	GL
27/06/17	Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities	GL
10/05/17	Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update	GL
24/04/17	Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting	GL
09/03/17	Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing	GL
07/03/17	Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call	GL
14/02/17	Newman Ferrara LLP : Announces Corporate Governance Investigation of Dimension Therapeutics Inc.	BU
07/02/17	Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors	GL
02/02/17	Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension Therapeutics, Inc.	BU
31/01/17	Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B	GL
13/12/16	Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency	GL
05/12/16	Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting	GL
29/11/16	Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)	GL